

Egyptian Co. for Production of

VACCINES,
Sera & Drugs
EGY VAC

الشركة المصرية لإنتاج الأمصال واللقاحات والأدوية غن.ت.م.م.
أحدى شركات الشركة القابضة للمستحضرات الحيوية واللقاحات

Company Profile



Securing future

Contents

- 1 History**
- 2-3 Chairmen of VACSERA**
- 4 Chairmen of EGYVAC**
- 5 Board of Directors of EGYVAC**
- 6 Area**
- 7 Mission & vision**
- 8 EGYVAC customers**
- 9 VACSERA abroad**



**10
11-25**

Products Portfolio Our products portfolio

- 12 Immune BCG-T
- 13 Tuberculin PPD
- 14 Human Insulin-Mix VACSERA
- 15 Polyvalent Anti Viper venom serum
- 16 Purified Polyvalent Anti-scorpion serum
- 17 Snake venom antiserum polyvalent
- 18 Diphtheria 10000 unit
- 19 Tetanus antitoxin 1500 IU (for prophylactic)
- 20 Anti-tetanic serum 30000 IU
- 21 Diphtheria, Tetanus and Pertussis vaccine Adsorbed D.T.P
- 22 Adsorbed Diphtheria-Tetanus vaccine D.T
- 23 Adsorbed Tetanus-diphtheria vaccine (T.d) for adult
- 24 Toxovac adsorbed tetanus toxoid vaccine
- 25 Cholera vaccine
- 26 Typhoid-Tetanus mix.



- 27 Corporate companies**
- 28 Imported products**
- 29 Pipeline products**

30-32 Projects in progress

- 31 Local production of Insulin in cooperation between EGYVAC and Novo Nordisk
- 31 Local production of seasonal and pandemic influenza vaccines
- 33 Local production of Rabies vaccines

History

- VACSERA was established in 1897 as a small laboratory by the Department of Health for the production of cholera vaccine.
- Vaccine production in Egypt dates back, however, to 1881 where smallpox was produced followed by rabies vaccine in 1907.
- VACSERA became a holding company in 2002 with three affiliate companies (EGYVAC, EGYBLOOD & EGYVET).
- VACSERA is a governmental company related to Egyptian Ministry of Health.





Shousha Pasha

was the first chairman of VACSERA

Afterwards, a number of chairmen followed

Aug.
1972
April
1974

1 Dr. El Sayed A. El Gebali

Jan.
1974
Aug.
1976

2 Dr. Abdou M. Sallam

Aug.
1976
May
1983

3 Dr. Emmam Zaghloul

May
1983
Feb.
1987

4 Dr. Aziz El Khouli

Feb.
1987
Nov.
1993

5 Dr. Ragaa Ali Hassan

Nov.
1993
Nov.
1994

6 Dr. Mashaalla H. Hosni

Dec.
1994
Aug.
1995

7 Dr. Kuka Saad Eldin

Sept.
1995
April
1996

8 Dr. Mohamed N. Nassar

April
1996
Aug.
1996

9 Dr. Hassan H. El Kalla

Aug.
1996
Aug.
1998

10 Dr. Nabil M. Omar

Aug.
1998
June
2006

11 Dr. Mohammed S. El Abbadi

July
2006
July
2011

12 Dr. Mohammed Rabie

Aug.
2011
July
2012

13 Dr. Adel Tolba

Aug.
2012
*till
present*

14 Dr. Raed Shokry



Chairman of EGYVAC

1



Dr. Salwa Seddik

2



Dr. Hamadellah Zidan

3



Dr. Nabil El Biblawy

Board members of EGYVAC

- 1 **Dr. Nabil El Beblawy** (*Chairman and Managing Director*)
- 2 **Dr. Ahmed Zaki Badr** (*Part time Member*)
- 3 **Dr. Samir Ismail Allam** (*Part time Member*)
- 4 **Dr. Alaa El Sayed Eid** (*Part time Member*)
- 5 **Dr. Faten Abd El Aziz** (*Part time Member*)
- 6 **Brig. General Dr. Ahmed Mgahed Saleh** (*Part time Member*)
- 7 **Dr. Maamon Zidan** (*Part time Member*)
- 8 **Dr. Heba Mahmoud Wali** (*Part time Member*)
- 9 **Mr. Hany Samy Mohamed** (*Part time Member*)
- 10 **Mr. Sayed Mostafa Gohar** (*Member of the Syndicate Committee*)

Area

Plots of land of about:



55000 m² in Agouza (Cairo)



95340 m² Helwan (Animal Husbandry)



60000 m² in 6th October governorate

Vision


To be recognized as a leader in the international biopharmaceutical & biotechnological industries, appreciated by our customers and respected by our competitors.

Mission


To produce, import and marketing of vaccines, sera & biological products to secure society requirements of vaccines & sera with commitment for continuous development of all activities.

EGYVAC customers

Satisfy our customer needs and series of regional needs



VACSERA abroad



Algeria Benin Cyprus Ethiopia Eritrea Iraq Lebanon Libya Niger North Korea Palestine Sudan Yemen

UNIVAX

Distributor for VACSERA

3Al-Andaluos st. - Roxy - Cairo

Tel: 24539374 / 22581663

Fax: 22594589

univaxvaccin@hotmail.com

Tchero Pharm

HOME OF VACCINES


14th Mostafa Mokhtar st., Heliopolis, Cairo, Egypt

Mobiles: 0122 199 1044, 0122 763 3363

Landline: +202 26202022 - 26244886

www.tchero.com

Vaccino



For Vaccines

٢ شارع قصر الطاهرة - الزيتون - القاهرة

2 a Kasr Eltahra st. - Elzaitoon - Cairo
Mobile : 01001112236 - 01001225240

vaccino4u@gmail.com

Our products portfolio

Include a wide range of high-value health-care products addressing prevention, treatment and diagnosis

- Immune BCG-T
- Tuberculin PPD
- Human Insulin-Mix VACSERA
- Polyvalent Anti Viper venom serum
- Polyvalent Anti-Scorpin venom serum
- polyvalent Anti-Snake venom serum
- Tetanus antitoxin 1500 IU
- Tetanus antitoxin 3000 IU
- Tetanus antitoxin 30000 IU
- Diphtheria, Tetanus and Pertussis vaccine DTPw
- Adsorbed Diphtheria-Tetanus vaccine D.T
- Adsorbed Diphtheria-Tetanus vaccine (T.d) for adult
- Adsorbed tetanus toxoid vaccine
- Typhoid vaccine
- Cholera vaccine
- Diphtheria vaccine
- Diphtheria 10000 unit
- Typhoid-Tetanous mix.




Immune BCG-T

Presentation:

- Vial 3ml (single dose) containing 90mg liquid BCG-T.

Indication:

- Treatment and prophylaxis of carcinoma in situ (cis) of the urinary bladder.
- Prophylaxis in primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection.



Tuberculin PPD

Presentation:

- Tuberculin (5 unit) vial 2ml (20 doses) one vial/box.

Indication:

- It is indicated as an aid in the diagnosis of tuberculosis.
- As a research in the epidemiological studies.



Human Insulin-Mix VACSERA

Presentation:

- Insulin-Mix (70/30) with two conc.
 - 100 IU/ml (vial 10ml)
 - 40 IU/ml (vial 10ml)

Indication:

- Diabetes mellitus in patients type I and type II when oral hypoglycemic is not sufficient.



Polyvalent Anti Viper venom serum

Presentation:

- 5ml vial (liquid) box.
- 5ml diluent + vial for lyophilized powder/box.

Indication:

- Treatment of envenomation caused by viper bites of any of the following:
 - CerastesCerastes
 - EchisCarinatus
 - CerastesVipera
 - PseudocerastesFieldi
 - EchisColoratus
 - ViperaLebatinae
 - Viperaammodytes
 - Vipera xanthine



Purified Polyvalent Anti-scorpion serum

Presentation:

- 1ml ampoule - 10 ampoules/box.
- One vial for the lyophilized powder + 1ml ampoule for the diluent (water for injection).

Indication:

- Treatment of envenomation from the stings of the following scorpion species:
 - Leiurusquinquestraitus
 - Androctonusameoreuxi
 - Androctonuscrassicauda
 - Androctonusaeneas
 - Androctonusausttrails
 - Scorpiomaruspalmatus
 - Buthusoccitans



Snake venom antiserum polyvalent

Presentation:

- 10ml vial (liquid) box.
- 10ml diluent + vial for lyophilized powder/box.

Indication:

- Treatment of envenomation caused by snake bites of any of the following species:
 - Najahaje
 - Najanigracollis
 - Watterinnesiaaegyptia
 - Ceraetescerastes
 - Cerastes vipers
 - Macrovipera palaestinae
 - Pseudocerastes persicus
 - Najamelanoleuca
 - Najaoxiana
 - Najamossambica
 - Bitisgabonica
 - Bitisareitans
 - Macrovipera lebetina
 - Vipera ammodytes
 - Echiscoloratus
 - Macrovipera lebetina
 - Vipera ammodytes
 - Echiscoloratus



Diphtheria 10000 unit

Presentation:

- Vial 5ml.

Indication:

- For treatment of diphtheria disease.



Tetanus antitoxin 1500 IU (for prophylactic)

Presentation:

- Ampoules of 1500 IU (boxes 10 ampoules).
- Vial 1ml.

Indication:

- Tetanus antitoxin is used for prophylaxis and treatment.



Anti-tetanic serum 30000 IU

Presentation:

- Vial of 10ml 30000 IU.

Indication:

- Serotherapy of tetanus.




Diphtheria, Tetanus & Pertussis vaccine Adsorbed D.T.P

Presentation:

- Vial 5ml (10 doses).

Indication:

- For the primary immunization of infants, above the age of six weeks and preschool children against diphtheria, tetanus and whooping cough.



Adsorbed Diphtheria–Tetanus vaccine D.T

Presentation:

- Vial 5ml (10 doses).
- Ampoule of 0.5ml (one dose).

Indication:

- The combined D.T vaccine recommended for active immunization against diphtheria and tetanus disease in children less than 7 years which can't take D.T.P due to convulsions.




Adsorbed Tetanus-diphtheria vaccine (T.d) for adult

Presentation:

- Vial 5ml (10 doses).
- Ampoule of 0.5ml (one dose).

Indication:

- Primary or secondary immunization in children aged (7 -12) years against tetanus and diphtheria.




Toxovac adsorbed tetanus toxoid vaccine

Presentation:

- Vial 5ml (10 doses).
- Ampoule of 0.5ml (10 ampoules/box).

Indication:

- Active primary and booster immunization in individuals 2 months of age or older when ever combined antigen preparations containing diphtheria and pertusis are contraindicated.
- Active immunization of mothers during pregnancy and child bearing age for protection of newborns against neonatal tetanus.
- Tetanus prophylaxis in wound management.




Cholera vaccine

Presentation:

- 10ml (20 doses).

Indication:

- Prophylaxis from cholera.



Typhoid–Tetanus mix.


Presentation:

- 10ml (20 doses).

Indication:

- Prophylaxis from typhoid & tetanus disease.





For Vaccines

٢٤ ش سفیان الثوری - سیدی بشر بحری - الإسكندرية
تلیفکس : ٠٣/٥٥٧٠٢٧٦ - موبایل : ٠١٠٠١٤١٣٩٠٢

24 Sofian Elsayry St., - Sidi Bishr - Alexandria
Tel.: 03/5570276 - Mobile : 01001413902

E-mail : bio_g_forvaccines@yahoo.com

Distributor for VACSERA

Corporate companies

- GlaxoSmithKline



- SANOFI PASTEUR



- MSD



- Pfizer



- LG



- EIMC



- Novo Nordisk



- SERUM INSTITUTE OF INDIA LTD.



- Biological E. Limited



Imported products

- Influenza vaccine
- Pneumococcal conjugate vaccine
- Pneumococcal polysaccharide vaccine
- Oral polio vaccine
- Injectable polio vaccine
- Rota vaccine
- Haemophilus influenza vaccine
- Penta vaccine
- Hepatitis A vaccine
- Hepatitis B vaccine
- Hepatitis A+B vaccine
- Hepatitis B immunoglobulin
- BCG VACCINE
- MMR vaccine
- VARICELLA vaccine
- MENINGITIS VACCINE
- Human papillomavirus (HPV)
- Rabies vaccine
- Rabies immunoglobulin
- Yellow fever vaccine
- IVIg



Pipeline products

- Meningitis AC vaccine (Registered soon).
- IPV (injectable polio vaccine) Technology transfer.
- Penta vaccine (Technology transfer).
- OCV (oral cholera vaccine) filling formulated bulk.



Dr. Ameer El-Feky

Consultant Of Pediatrics

Member Of AAP (USA)

IBCLC (USA)



د. أمير الفقي

استشاري طب الأطفال و حديثي الولادة
دكتوراه طب الأطفال - مستشفى أبو الريش - جامعة القاهرة
عضو الأكاديمية الأمريكية لطب الأطفال
إستشاري دولي معتمد للرضاعة الطبيعية

ADDRESS: NEW MAADI , 1 St. 270

 maadipediatic

 01000 185 777

مركز تطعيمات أرب فاك

مركز معتمد

المصل و اللقاح



Vaccination Center Authorised From EGYVAC (VACSERA)

ADDRESS: NEW MAADI , 1 St. 270

 010 20 25 6600





Projects in progress

Local production of Insulin in cooperation between EGYVAC and Novo Nordisk

Objective:

To manufacture local insulin at 6th October Site with collaboration with Novo Nordisk.

Project Activity:

Produce local insulin to cover Egyptian market demand, start in production by 2018.

Project capacity:

Maximum capacity of project is 25 million vials per year.

Time frame and marketing capacity of project:

- *Phase 1 (Secondary packaging):*
 - 2.5 years till plant is ready for production.
 - Market capacity 10 million vials.
- *Phase 2 (Full formulation and Filling):*
 - 25 million vials as maximum capacity in 2026.



Local production of seasonal and pandemic influenza vaccines

Objective:

Establishment of a Pilot Facility for the production of seasonal and pandemic influenza vaccines in 6th October Site with collaboration of WHO, ADVENS, RIVM.

Project Activity:

- Establish, test and completely document an egg-based influenza production facility.
- A Letter of Agreement (LA), between WHO and VACSERA/EGYVAC was concluded and signed on 1 July 2009 whereby WHO agrees to provide financial support to project US\$ 1.5 million for the first phase of the project.

Project capacity:

initial capacity of 500,000 doses of trivalent seasonal influenza per year, with expansion possibilities up to 1.5 million doses seasonal influenza and 20 million doses monovalent pandemic vaccine per annum.



Time frame:

The project will be carried out in phases over a period of three years.



Local production of Rabies vaccines

Objective:

To manufacture Rabies vaccine at Agouza Site with collaboration with Bari Consultants Company.

Project capacity:

Maximum capacity of project is 2 million dose per year.

Time frame and marketing:

The project will be carried out over a period of two years.



 **Egyptian Company for Production of Vaccines, Sera & Drugs**

51 Wezaret El-Zeraa St., Giza, Egypt

Tel: (+202) 37 61 11 11

www.vacsera.com

 <https://www.facebook.com/VacseraNews>

 [Vacsera News@Vacsera_News](mailto:Vacsera_News@Vacsera_News)

 https://www.youtube.com/channel/UC_ApWgOA2TuotChiKPo414w

VACSERA

Egyptian Co. for Production of

VACCINES,
Sera & Drugs
EGY VAC

الشركة المصرية لإنتاج الأمصال والتفاعات والأجوية ش.ت.م.
أحدى شركات الشركة القابضة للمستحضرات الحيوية والتفاعات